Concepts (87)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chromosomes, Human | 1 | 2014 | 129 | 0.460 |
Why?
|
| Chromosome Mapping | 2 | 2022 | 1079 | 0.430 |
Why?
|
| Cholesterol, HDL | 1 | 2014 | 358 | 0.420 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2012 | 13 | 0.410 |
Why?
|
| Receptors, Thrombin | 1 | 2012 | 12 | 0.410 |
Why?
|
| Triglycerides | 1 | 2014 | 574 | 0.390 |
Why?
|
| Cholesterol, LDL | 1 | 2014 | 567 | 0.360 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2022 | 2629 | 0.330 |
Why?
|
| Blood Pressure | 1 | 2012 | 1351 | 0.270 |
Why?
|
| Sarcoma, Synovial | 1 | 2024 | 21 | 0.230 |
Why?
|
| Margins of Excision | 1 | 2024 | 52 | 0.230 |
Why?
|
| Neonatal Screening | 1 | 2024 | 184 | 0.200 |
Why?
|
| Breast Neoplasms | 5 | 2012 | 2497 | 0.190 |
Why?
|
| Congenital Abnormalities | 1 | 2024 | 255 | 0.180 |
Why?
|
| Hepatoblastoma | 1 | 2023 | 179 | 0.180 |
Why?
|
| Obesity | 1 | 2012 | 2262 | 0.180 |
Why?
|
| Hepatitis C | 1 | 2022 | 366 | 0.150 |
Why?
|
| Liver Cirrhosis | 1 | 2022 | 831 | 0.120 |
Why?
|
| DNA Methylation | 2 | 2012 | 1002 | 0.120 |
Why?
|
| Prognosis | 6 | 2024 | 4608 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 1310 | 0.110 |
Why?
|
| Receptors, Progesterone | 3 | 2012 | 878 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2012 | 39 | 0.100 |
Why?
|
| LIM Domain Proteins | 1 | 2012 | 59 | 0.100 |
Why?
|
| ErbB Receptors | 2 | 2012 | 282 | 0.100 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2012 | 83 | 0.100 |
Why?
|
| Family | 1 | 2014 | 562 | 0.090 |
Why?
|
| Cadherins | 1 | 2012 | 166 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 2 | 2012 | 1328 | 0.090 |
Why?
|
| Female | 11 | 2024 | 66301 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 464 | 0.080 |
Why?
|
| Aged, 80 and over | 3 | 2014 | 6465 | 0.070 |
Why?
|
| Carcinoma, Lobular | 1 | 2008 | 24 | 0.070 |
Why?
|
| Mastectomy | 1 | 2008 | 64 | 0.070 |
Why?
|
| Middle Aged | 7 | 2022 | 26605 | 0.070 |
Why?
|
| Male | 6 | 2024 | 61018 | 0.070 |
Why?
|
| Cytokines | 1 | 2012 | 1289 | 0.070 |
Why?
|
| Humans | 12 | 2024 | 124227 | 0.060 |
Why?
|
| Quality of Health Care | 1 | 2008 | 388 | 0.060 |
Why?
|
| Recurrence | 2 | 2023 | 1420 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2008 | 468 | 0.060 |
Why?
|
| Aged | 5 | 2014 | 19545 | 0.060 |
Why?
|
| Anemia, Sickle Cell | 1 | 2008 | 338 | 0.060 |
Why?
|
| Receptors, Estrogen | 3 | 2012 | 797 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 2044 | 0.050 |
Why?
|
| Mass Screening | 1 | 2008 | 781 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 1942 | 0.050 |
Why?
|
| Treatment Outcome | 5 | 2023 | 12272 | 0.050 |
Why?
|
| Reoperation | 1 | 2024 | 829 | 0.050 |
Why?
|
| Adult | 4 | 2014 | 29367 | 0.040 |
Why?
|
| Stroke | 1 | 2008 | 976 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2022 | 243 | 0.040 |
Why?
|
| Receptor, ErbB-2 | 2 | 2012 | 514 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 1133 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2024 | 16276 | 0.040 |
Why?
|
| Registries | 1 | 2024 | 1422 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2012 | 1233 | 0.030 |
Why?
|
| Genotype | 1 | 2022 | 2556 | 0.030 |
Why?
|
| Texas | 1 | 2024 | 3583 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2024 | 14000 | 0.030 |
Why?
|
| Ploidies | 1 | 2012 | 37 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 356 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2024 | 8189 | 0.020 |
Why?
|
| Gene Order | 1 | 2011 | 79 | 0.020 |
Why?
|
| CpG Islands | 1 | 2012 | 323 | 0.020 |
Why?
|
| Frozen Sections | 1 | 2010 | 25 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2011 | 406 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2010 | 100 | 0.020 |
Why?
|
| Tamoxifen | 1 | 2011 | 363 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2011 | 256 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1422 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2010 | 411 | 0.020 |
Why?
|
| Infant | 1 | 2023 | 12464 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2008 | 107 | 0.020 |
Why?
|
| Child | 2 | 2024 | 24354 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 1491 | 0.020 |
Why?
|
| Adolescent | 1 | 2024 | 19260 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 866 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 1029 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 1890 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 5127 | 0.010 |
Why?
|
| Age Factors | 1 | 2010 | 2808 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2008 | 1173 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 2036 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 841 | 0.010 |
Why?
|
| Phenotype | 1 | 2010 | 4252 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2008 | 4779 | 0.010 |
Why?
|